

CUSTOMER NUMBER 25268

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sikdar et al. Attorney Docket No. UNIV0350
Serial No.: 10/574,133 Group Art Unit: 3737
Filed: March 30, 2006 Confirmation No. 7922
Title: TRANSCUTANEOUS LOCALIZATION OF ARTERIAL BLEEDING BY
TWO-DIMENSIONAL ULTRASONIC IMAGING OF TISSUE VIBRATIONS

INFORMATION DISCLOSURE STATEMENT

Bellevue, Washington 98004

June 26, 2006

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. Copies of the listed Foreign Patent Documents and Other Information are enclosed for the Examiner's use.

2. Copies of the listed patents, publications, and other information were previously cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. 11/218,292 filed August 31, 2005, and relied upon for an earlier filing date under 35 U.S.C. § 120.

3. Documents cited herein marked with an “**” have not previously been cited in a priority application relied upon herein for an earlier filing date. Copies of any so-noted Foreign Patent Documents and Other Information are enclosed for the Examiner's use.

4. A concise explanation of the relevance of document I.D. No. _____ (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided _____.

5. Pursuant to 37 C.F.R. § 1.97(b), this information disclosure statement is being filed within three months of the filing date of the national application, within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits.

UNIV0350-1-21\0350 163.doc

6. Submission with RCE: Pursuant to 37 C.F.R. § 1.114, this information disclosure statement is being submitted concurrently with a Request for Continued Examination (RCE) in the above-identified application.

7. Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:

 - _____ a certification as specified in 37 C.F.R. § 1.97(e); or
 - _____ the fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$ _____ is enclosed.

8. Pursuant to 37 C.F.R. § 1.97(d), this information disclosure statement is being filed after the mailing date of either:

 - _____ a final action under 37 C.F.R. § 1.113; or
 - _____ a notice of allowance under 37 C.F.R. § 1.311,

but before payment of the issue fee. The statement is accompanied by a certification as specified in 37 C.F.R. § 1.97(e), a statement requesting consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$ _____ is enclosed.

9. Please charge any additional fees or credit any overpayment to Deposit Account No. 01-1940.

Respectfully submitted,

/ron anderson/
Ronald M. Anderson
Registration No. 28,829